Jacobson Pharma Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Jacobson Pharma.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth	10.8%
Revenue growth rate	n/a
Future return on equity	n/a
Analyst coverage	None
Last updated	n/a

Recent future growth updates

Recent updates

There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump

Nov 22

Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Aug 21

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Dec 21

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

Nov 27

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jun 20

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Nov 28

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Sep 25

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Sep 16

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 28

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Sep 16

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Feb 03

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Jan 24

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Jan 11

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Dec 27

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

Dec 12

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Dec 03

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Jacobson Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

SEHK:2633 - Analysts future estimates and past financials data (HKD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
9/30/2024	1,563	253	N/A	N/A	N/A
6/30/2024	1,515	220	N/A	N/A	N/A
3/31/2024	1,468	186	355	484	N/A
12/31/2023	1,811	221	N/A	N/A	N/A
9/30/2023	1,919	217	485	598	N/A
6/30/2023	1,852	234	526	614	N/A
3/31/2023	1,268	175	567	630	N/A
12/31/2022	1,489	207	466	517	N/A
9/30/2022	1,427	203	364	403	N/A
6/30/2022	1,511	190	354	405	N/A
3/31/2022	1,596	178	343	407	N/A
12/31/2021	1,548	166	N/A	N/A	N/A
9/30/2021	1,501	154	427	490	N/A
6/30/2021	1,473	164	386	450	N/A
3/31/2021	1,446	174	346	409	N/A
12/31/2020	1,478	183	N/A	N/A	N/A
9/30/2020	1,510	191	257	335	N/A
6/30/2020	1,541	203	267	348	N/A
3/31/2020	1,571	214	277	361	N/A
9/30/2019	1,419	273	523	444	N/A
6/30/2019	1,449	259	437	420	N/A
3/31/2019	1,478	245	352	396	N/A
12/31/2018	1,663	235	259	361	N/A
9/30/2018	1,622	219	166	326	N/A
6/30/2018	1,585	211	N/A	284	N/A
3/31/2018	1,549	202	N/A	243	N/A
12/31/2017	1,486	202	N/A	217	N/A
9/30/2017	1,424	203	N/A	190	N/A
6/30/2017	1,340	191	N/A	177	N/A
3/31/2017	1,256	179	N/A	164	N/A
12/31/2016	1,188	142	N/A	177	N/A
9/30/2016	1,141	142	N/A	230	N/A
6/30/2016	1,112	144	N/A	226	N/A
3/31/2016	1,084	146	N/A	221	N/A
12/31/2015	1,043	145	N/A	220	N/A
3/31/2015	948	102	N/A	162	N/A
3/31/2014	926	172	N/A	150	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 2633's forecast earnings growth is above the savings rate (2.3%).

Earnings vs Market: Insufficient data to determine if 2633's earnings are forecast to grow faster than the Hong Kong market

High Growth Earnings: Insufficient data to determine if 2633's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if 2633's revenue is forecast to grow faster than the Hong Kong market.

High Growth Revenue: Insufficient data to determine if 2633's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if 2633's Return on Equity is forecast to be high in 3 years time

Jacobson Pharma Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target lowered to HK$1.65

Recent updates

Jacobson Pharma Corporation Limited Announces the Interim Dividend for the Six Months Ended 30 September 2024, Payable on 02 April 2025

There's Reason For Concern Over Jacobson Pharma Corporation Limited's (HKG:2633) Massive 27% Price Jump

Jacobson Pharma Corporation Limited Announces the Interim Dividend for the Six Months Ended 30 September 2024

Europharm Laboratoires Company Limited agreed to acquire 20.10% stake in Li Chung Shing Tong (Holdings) Limited from Jacobson Pharma Corporation Limited (SEHK:2633) for HKD 46.2 million.

Jacobson Pharma Corporation Limited to Report First Half, 2025 Results on Nov 21, 2024

Jacobson Pharma Corporation Limited Approves Final Cash Dividend for the Year Ended 31 March 2024

Upcoming dividend of HK$0.03 per share

Increases to Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Might Cool off for now

Jacobson Pharma Corporation Limited, Annual General Meeting, Aug 28, 2024

Full year 2024 earnings released: EPS: HK$0.11 (vs HK$0.13 in FY 2023)

Jacobson Pharma Corporation Limited has completed a Follow-on Equity Offering in the amount of HKD 39.6 million.

New minor risk - Shareholder dilution

Jacobson Pharma's (HKG:2633) Profits May Not Reveal Underlying Issues

Upcoming dividend of HK$0.025 per share at 7.7% yield

First half 2024 earnings released: EPS: HK$0.053 (vs HK$0.077 in 1H 2023)

Jacobson Pharma's (HKG:2633) Dividend Is Being Reduced To HK$0.025

New minor risk - Earnings quality

Jacobson Pharma Corporation Limited Announces Interim Dividend for the Six Months Ended September 30, 2023, Payable on 10 January 2024

Jacobson Pharma Corporation Limited to Report Q2, 2024 Results on Nov 24, 2023

New minor risk - Share price stability

Now 40% undervalued after recent price drop

Upcoming dividend of HK$0.024 per share at 5.3% yield

Jacobson Pharma Corporation Limited, Annual General Meeting, Aug 01, 2023

These 4 Measures Indicate That Jacobson Pharma (HKG:2633) Is Using Debt Reasonably Well

Jacobson Pharma Corporation Limited Proposes Final Dividend for the Year Ended 31 March 2023, Payable on 1 September 2023

Full year 2023 earnings released: EPS: HK$0.13 (vs HK$0.093 in FY 2022)

Jacobson Pharma Corporation Limited to Report Fiscal Year 2023 Results on Jun 15, 2023

Upcoming dividend of HK$0.028 per share

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Jacobson Pharma Corporation Limited Announces Interim Dividend for the Six Months Ended 30 September 2022, Payable on 29 December 2022

First half 2023 earnings released: EPS: HK$0.071 (vs HK$0.042 in 1H 2022)

Less than half of directors are independent

Jacobson Pharma Corporation Limited to Report First Half, 2023 Results on Nov 25, 2022

Upcoming dividend of HK$0.027 per share

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.0268

Jacobson Pharma Corporation Limited Approves Final Dividend for the Year Ended 31 March 2022

Should Shareholders Reconsider Jacobson Pharma Corporation Limited's (HKG:2633) CEO Compensation Package?

Jacobson Pharma's (HKG:2633) Shareholders Will Receive A Bigger Dividend Than Last Year

Jacobson Pharma Corporation Limited, Annual General Meeting, Sep 23, 2022

Jacobson Pharma's (HKG:2633) Upcoming Dividend Will Be Larger Than Last Year's

Chairman recently bought HK$1.6m worth of stock

Full year 2022 earnings released

Jacobson Pharma Corporation Limited Proposes Final Dividend for the Year Ended 31 March 2022, Payable on 18 October 2022

Jacobson Pharma Corporation Limited to Report Fiscal Year 2022 Results on Jun 29, 2022

Less than half of directors are independent

Chairman recently bought HK$237k worth of stock

Does Jacobson Pharma (HKG:2633) Have A Healthy Balance Sheet?

Chairman recently bought HK$341k worth of stock

Chairman recently bought HK$377k worth of stock

Upcoming dividend of HK$0.012 per share

Jacobson Pharma (HKG:2633) Is Increasing Its Dividend To HK$0.012

First half 2022 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of HK$0.015 per share

Jacobson Pharma (HKG:2633) Is Reducing Its Dividend To HK$0.015

Here's Why It's Unlikely That Jacobson Pharma Corporation Limited's (HKG:2633) CEO Will See A Pay Rise This Year

Full year 2021 earnings released: EPS HK$0.091 (vs HK$0.11 in FY 2020)

The board of Jacobson Pharma Corporation Limited (SEHK:2633) completed the spin off of an unknown stake of Branded healthcare business.

Independent Non-Executive Director recently bought HK$144k worth of stock

Kwing Tong Lam Is The Independent Non-Executive Director of Jacobson Pharma Corporation Limited (HKG:2633) And They Just Picked Up 28% More Shares

Investor sentiment deteriorated over the past week

New 90-day low: HK$1.07

A Look At The Fair Value Of Jacobson Pharma Corporation Limited (HKG:2633)

Here's Why Jacobson Pharma (HKG:2633) Has A Meaningful Debt Burden

Does Jacobson Pharma's (HKG:2633) CEO Salary Compare Well With The Performance Of The Company?

Second quarter 2021 earnings released: EPS HK$0.027

Is It Smart To Buy Jacobson Pharma Corporation Limited (HKG:2633) Before It Goes Ex-Dividend?

New 90-day high: HK$1.20

Reflecting on Jacobson Pharma's (HKG:2633) Share Price Returns Over The Last Three Years

Second quarter 2021 earnings released: EPS HK$0.027

New 90-day low: HK$1.11

Jacobson Pharma Corporation Limited to Report Q2, 2021 Results on Nov 27, 2020

Price target lowered to HK$1.65

New 90-day low - HK$1.20

Earnings and Revenue Growth Forecasts